Peyrin-Biroulet L - Search Results

1

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.

2

Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.

Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Peyrin-Biroulet L, et al. World J Gastroenterol. 2007 Apr 28;13(16):2328-32. doi: 10.3748/wjg.v13.i16.2328. World J Gastroenterol. 2007. PMID: 17511032 Free PMC article. Clinical Trial.

3

Antimycobacterial therapy in Crohn's disease: game over?

Peyrin-Biroulet L, Neut C, Colombel JF. Peyrin-Biroulet L, et al. Gastroenterology. 2007 Jun;132(7):2594-8. doi: 10.1053/j.gastro.2007.04.027. Gastroenterology. 2007. PMID: 17570230 Review. No abstract available.

4

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53. doi: 10.1016/j.cgh.2008.03.014. Clin Gastroenterol Hepatol. 2008. PMID: 18550004

5

Early combined immunosuppression in Crohn's disease.

Danese S, Peyrin-Biroulet L. Danese S, et al. Lancet. 2008 Jun 14;371(9629):1996; author reply 1996-7. doi: 10.1016/S0140-6736(08)60862-4. Lancet. 2008. PMID: 18555908 No abstract available.

6

Crohn's disease: beyond antagonists of tumour necrosis factor.

Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Peyrin-Biroulet L, et al. Lancet. 2008 Jul 5;372(9632):67-81. doi: 10.1016/S0140-6736(08)60995-2. Lancet. 2008. PMID: 18603161 Review.

7

Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease.

Parmentier-Decrucq E, Duhamel A, Ernst O, Fermont C, Louvet A, Vernier-Massouille G, Cortot A, Colombel JF, Desreumaux P, Peyrin-Biroulet L. Parmentier-Decrucq E, et al. Inflamm Bowel Dis. 2009 Oct;15(10):1476-84. doi: 10.1002/ibd.20931. Inflamm Bowel Dis. 2009. PMID: 19291781

8

Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease.

Peyrin-Biroulet L, Colombel JF, Sandborn WJ. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1139. doi: 10.1016/j.cgh.2009.05.012. Epub 2009 May 22. Clin Gastroenterol Hepatol. 2009. PMID: 19465159 No abstract available.

9

Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.

Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, Lémann M, Colombel JF. Peyrin-Biroulet L, et al. Am J Gastroenterol. 2009 Aug;104(8):2089-96. doi: 10.1038/ajg.2009.301. Epub 2009 Jun 30. Am J Gastroenterol. 2009. PMID: 19568226 Review.

10

Ulcerative colitis: Natural history--an optimistic message from Norway.

Peyrin-Biroulet L, Colombel JF. Peyrin-Biroulet L, et al. Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):387-8. doi: 10.1038/nrgastro.2009.100. Nat Rev Gastroenterol Hepatol. 2009. PMID: 19575022 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,038 results

Search Page